Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis

Multiple Sclerosis Clinical Trial

Official title:

Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01933802
• Other study ID #: TISCHMS-MSCNP-001
• Secondary ID: IND 13889
• Status: Completed
• Phase: Phase 1
• First received: August 23, 2013
• Last updated: March 15, 2018
• Start date: April 2014
• Est. completion date: March 2017

Study information

• Verified date: March 2018
• Source: Tisch Multiple Sclerosis Research Center of New York
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is an open-label, phase I clinical trial designed to evaluate the safety and tolerability of intrathecal administration of autologous mesenchymal stem cell-derived neural progenitor cells (MSC-NP) in patients with progressive multiple sclerosis. Study participants will receive three intrathecal injections of culture-expanded autologous MSC-NPs at three month intervals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: March 2017
• Est. primary completion date: December 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Diagnosis of MS as defined by the McDonald criteria

• Diagnosis of primary progressive or secondary progressive MS

• Between the ages of 18-70 years

• Significant disability shown by an Expanded Disability Status Score (EDSS) of 3.0 or greater that was not acquired within the last 12 months

• Stable disease state as evidenced by a lack of gadolinium-enhancing lesions on an MRI and by a stable MRI disease burden (number of T2 lesions and size of lesions) in the last six months and no significant change in EDSS (1 point or more) in the last 12 months

• Must agree to undergo MRIs at the time of enrollment, 2 months after the first treatment, and 27 months after the last treatment

• Live in northern New Jersey, southern New York, or southwestern Connecticut during the study period, or patients must be able to arrange reliable travel accommodations to be present for every study visit if they live farther away.

Exclusion Criteria:

• Pregnant or nursing mothers or any woman intending to become pregnant in the next three years

• All patients will have pre-study liver function tests, PT/PPT, platelets, hematocrit, and renal function laboratory tests done. Only patients whose values are in the normal range as determined by the laboratory norms based on age and sex will be allowed to participate.

• Use of systemic chemotherapeutic or anti-mitotic medications within three months of study start date due to the possibility of interference with bone marrow procedure

• Any patients with a history of or with active malignancy

• Use of steroids within three months of the study start date, as this would suggest a highly active disease state

• History of cirrhosis due to increased risk of central nervous system (CNS) infection

• Poorly controlled hypertension because of increased risk for stroke or CNS hemorrhage. Specifically, any patient with a systolic blood pressure value of = 145 mm/Hg or a diastolic blood pressure value of = 95 mm/Hg will be excluded from study participation.

• History of thyroid disorders or other endocrine disorders because of hormone influence on cell growth

• History of central nervous system infection or immunodeficiency syndromes due to increased risk of CNS infection

• Preexisting blood disease (such as bone marrow hypoplasia, leukopenia, thrombocytopenia, or significant anemia) due to invasive nature of bone-marrow aspiration

• Previous or current history of a coagulation disorder

• Any metal in the body, which is contraindicated for MRI studies

• Allergy to any of the antibiotics used in this study, e.g. tobramycin, vancomycin, or gentamicin

• Patients with alcohol or other substance abuse problems

• Other major disease that, in the opinion of the Principal Investigator, would preclude participation in the study

• Patients with HBV, HCV, syphilis, HIV-1, or HIV-2.

• Any evidence of significant cognitive dysfunction based on a screening history and physical examination because it would preclude giving a truly informed consent

• Patients who are enrolled in another clinical trial for MS treatment or who have received any study drug/biologics within the last 6 months

Related Conditions & MeSH terms

• Multiple Sclerosis
• Sclerosis

Intervention

Biological:
• intrathecal administration of autologous MSC-NP
Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.

Locations

Country	Name	City	State
United States	Tisch MS Research Center of New York	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Tisch Multiple Sclerosis Research Center of New York

Country where clinical trial is conducted

United States, 

References & Publications (3)

Harris VK, Faroqui R, Vyshkina T, Sadiq SA. Characterization of autologous mesenchymal stem cell-derived neural progenitors as a feasible source of stem cells for central nervous system applications in multiple sclerosis. Stem Cells Transl Med. 2012 Jul;1(7):536-47. doi: 10.5966/sctm.2012-0015. Epub 2012 Jun 28. — View Citation

Harris VK, Stark J, Vyshkina T, Blackshear L, Joo G, Stefanova V, Sara G, Sadiq SA. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis. EBioMedicine. 2018 Feb 3. pii: S2352-3964(18)30051-3. doi: — View Citation

Harris VK, Yan QJ, Vyshkina T, Sahabi S, Liu X, Sadiq SA. Clinical and pathological effects of intrathecal injection of mesenchymal stem cell-derived neural progenitors in an experimental model of multiple sclerosis. J Neurol Sci. 2012 Feb 15;313(1-2):167-77. doi: 10.1016/j.jns.2011.08.036. Epub 2011 Oct 1. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events	The primary objective of the study is to assess the safety and tolerability of intrathecal therapy with autologous MSCNPs in MS. Number of participants with adverse events will be documented 1 day, 1 week, 1 month and 2 months post treatment for three treatments (followup for third treatment is 3 months instead of 2 months).	9 months
Primary	Number of participants with adverse events .	The co-primary objective will be to observe long term safety of the treatment 6 months and 30 months following the last treatment.	30 months
Secondary	Preliminary evaluation of efficacy	The secondary objective is to observe trends in efficacy over the course of the experimental treatment. Outcome measures include evoked potentials (baseline and 3 months post 3rd dose) ,quality of life questionnaire, EDSS, and MSFC (baseline, at the time of each dose, and 3 and 6 months after third dose), and MRI (baseline, 2 months after first dose, and 3 and 24 months after third dose).	9 months

External Links

•   Tisch MS Research Center of New York